Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study
Pasquale Niscola
No information about this author
The Lancet Haematology,
Journal Year:
2025,
Volume and Issue:
12(2), P. e88 - e90
Published: Feb. 1, 2025
Language: Английский
Research and analysis of differential gene expression in CD34 hematopoietic stem cells in myelodysplastic syndromes
PLoS ONE,
Journal Year:
2025,
Volume and Issue:
20(3), P. e0315408 - e0315408
Published: March 12, 2025
Objective
This
study
aims
to
investigate
and
analyze
the
differentially
expressed
genes
(DEGs)
in
CD34
+
hematopoietic
stem
cells
(HSCs)
from
patients
with
myelodysplastic
syndromes
(MDS)
through
bioinformatics
analysis,
ultimate
goal
of
uncovering
potential
molecular
mechanisms
underlying
pathogenesis
MDS.
The
findings
this
are
expected
provide
novel
insights
into
clinical
treatment
strategies
for
Methods
Initially,
we
downloaded
three
datasets,
GSE81173,
GSE4619,
GSE58831,
public
Gene
Expression
Omnibus
(GEO)
database
as
our
training
sets,
selected
GSE19429
dataset
validation
set.
To
ensure
data
consistency
comparability,
standardized
sets
removed
batch
effects
using
ComBat
algorithm,
thereby
integrating
them
a
unified
gene
expression
dataset.
Subsequently,
conducted
differential
analysis
identify
significant
changes
levels
across
different
disease
states.
In
order
enhance
prediction
accuracy,
incorporated
six
common
predictive
models
trained
based
on
filtered
After
comprehensive
evaluation,
ultimately
algorithms—Lasso
regression,
random
forest,
support
vector
machine
(SVM)—as
core
models.
more
precisely
pinpoint
closely
related
characteristics,
utilized
aforementioned
learning
methods
took
intersection
these
results,
yielding
robust
list
associated
features.
Following
this,
in-depth
key
set
validated
results
independently
Furthermore,
performed
groups,
co-expression
enrichment
delve
deeper
roles
initiation
progression.
Through
analyses,
aim
new
foundations
diagnosis
treatment.
Figure
illustrates
preprocessing
workflow
study.
Results
Our
CD34+
revealed
differences
patterns
compared
control
group
(individuals
without
MDS).
Specifically,
two
genes,
IRF4
ELANE,
were
notably
downregulated
HSCs
MDS
patients,
indicating
their
downregulatory
pathological
process
Conclusion
sheds
light
MDS,
particular
focus
pivotal
ELANE
pathogenic
genes.
perspective
understanding
complexity
exploring
therapeutic
strategies.
They
may
also
guide
development
precise
effective
treatments,
such
targeted
interventions
directed
against
Language: Английский
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients
Expert Review of Hematology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 31, 2025
Introduction
Older
patients
with
acute
myeloid
leukemia
(AML)
are
often
unsuitable
for
standard
treatments
and
traditionally
have
a
dismal
prognosis.
For
20
years,
hypomethylating
agents
(HMAs),
as
single
recently
backbone
venetoclax,
been
used
in
this
setting.
The
oral
combination
of
decitabine
cedazuridine
(C-DEC),
which
is
therapeutically
pharmacologically
equivalent
to
the
intravenous
(IV)
formulation
(IV-DEC),
has
expanded
therapeutic
arsenal
AML,
allowing
better
convenience
administration.
This
review
provides
an
overview
C-DEC,
current
clinical
applications,
ongoing
studies,
highlighting
its
potential
role
managing
AML
older
patients.
Language: Английский
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Current Oncology,
Journal Year:
2024,
Volume and Issue:
31(11), P. 6632 - 6658
Published: Oct. 24, 2024
Acute
myeloid
leukemia
(AML)
is
a
heterogeneous
blood-related
neoplasm
that
predominantly
afflicts
older
adults
with
poor
prognosis
due
to
their
physical
condition
and
the
presence
of
medical
accompanying
comorbidities,
adverse
biological
disease
features,
suitability
for
induction
intensive
chemotherapy
allogenic
stem
cells
transplantation.
Recent
research
into
molecular
factors
contributing
development
progression
has
led
significant
advancements
in
treatment
approaches
patients
AML.
This
review
article
discusses
latest
therapeutic
developments
are
transforming
management
AML
adults.
Language: Английский
Genetic Predisposition to Myelodysplastic Syndrome: Genetic Counseling and Transplant Implications
Seminars in Hematology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 1, 2024
Language: Английский
Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments
Published: June 24, 2024
Acute
myeloid
leukemias
(AMLs)
are
heterogeneous
hematologic
cancers
that
occur
prevalently
in
older
patients
as
the
result
of
a
complex
pathobiology.
The
clinical
outcomes
with
AML,
often
unsuitable
for
intensive
chemotherapy
and
allogeneic
stem
cell
transplantation,
generally
disappointing.
However,
recent
advances
understanding
molecular
pathogenesis
other
biological
mechanisms
recognized
AML
development
progression
have
changed
treatment
approach,
especially
this
particularly
vulnerable
category
patients.
Indeed,
non-intensive
biologically
tailored
approaches,
such
combining
venetoclax
hypomethylating
agents,
therapeutic
paradigm
field.
Moreover,
promising
compounds
strategies
currently
under
advanced
development.
This
article
delves
into
latest
management
new
conceptual
frameworks
progressively
transform
practice
challenging
setting.
Language: Английский
Quality of life considerations in myelodysplastic syndrome: not only fatigue
Expert Review of Hematology,
Journal Year:
2024,
Volume and Issue:
17(8), P. 407 - 410
Published: July 6, 2024
KEYWORDS:
myelodysplastic
syndrome
(MDS)quality
of
life
(QOL)sleepphysical
exerciselifestylepsychologyclinical
treatment
Language: Английский